Bambusa Therapeutics: First Subject Dosed in BBT002 Phase 1 Trial
30 May 2025 //
PR NEWSWIRE
I&I Startup Bambusa Nabs $90M for Bispecific Antibodies
14 Feb 2025 //
BIOSPACE
Bambusa Therapeutics Secures Seed Funding For Bispecific Antibodies
09 Sep 2024 //
PR NEWSWIRE